Twitxy
Saved
@DrNeilGross's profile picture
View on X

Neil D. Gross, MD, FACS

@DrNeilGross

Professor, Head & Neck Surgery & Director of Perioperative Surgical Services. Expert in neoadjuvant trials. Husband, father and outdoor enthusiast.
Houston, TX faculty.mdanderson.org/Neil_Gross/ Joined May 2016
887 Following 2K Followers 1.7K Posts

Latest posts 5

Pinned post

Neil D. Gross, MD, FACS @DrNeilGross
🗞️ today in @Nature! Incredible work led by ⁦@moranamit2⁩ #OncSurgery ⁦@MDAndersonNews⁩ translating our findings using #neoadjuvant #immunotherapy in #skin #CSCC cancer ⁦@AACR⁩ ⁦@NEJM⁩ into a novel understanding of cancer biology. nature.com/articles/s4158…
www.nature.com Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy Nature - Perineural invasion and cancer-induced nerve injury of tumour-associated nerves are associated with poor response to anti-PD-1 therapy, which can be reversed by combining anti-PD-1 therapy...
3 replies 6 reposts 57 likes 4.3K views View on X
Neil D. Gross, MD, FACS @DrNeilGross
Breaking News! 🗞️ Published today in @JCO_ASCO and presented simultaneously at @myESMO. Long-term survival remains excellent 📈 after #neoadjuvant #Immunotherapy for advanced resectable @SquamousCscc #skincancer. #OncSurgery #EndCancer @UTMDAnderson
ascopubs.org/doi/10.1200/JC…
ascopubs.org Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma:... We previously reported the results of a multicenter phase II trial (ClinicalTrials.gov identifier: NCT04154943) of neoadjuvant cemiplimab in resectable stage II to IV cutaneous squamous cell carcin...
1 replies 8 reposts 28 likes 1.6K views View on X
Neil D. Gross, MD, FACS @DrNeilGross
So proud of the huge efforts led by @moranamit2 to help unlock the biology of non-melanoma #skincancer in immunosuppressed patients! @ShorookNa #OncSurgery @MDAndersonnews 🗞️
Cell cell.com/cell/fulltext/…
www.cell.com Spatial biology reveals altered macrophage states in immunosuppressed non-melanoma skin cancer Spatial multi-omics reveals macrophage states that constrain adaptive immunity in immunosuppressed non-melanoma skin cancer.